Ocular symptoms and signs with preserved and preservative-free glaucoma medications

European Journal of Ophthalmology

Volumn 17, Issue 3, 2007, Pages 341-349

  Jaenen, N ^a   Baudouin, C ^b   Pouliquen, P ^c   Manni, G ^d   Figueiredo, A ^e   Zeyen, Thierry ^a,f  

^a Gelaat en Halschirurgie   (Belgium)

^b XV XX Hospital   (France)

^c Laboratoires Thea   (France)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^e HOSPITAL DE SANTA MARIA   (Portugal)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Glaucoma; Preserved and preservative free eyedrops; Side effects

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG PRESERVATIVE; EYE DROPS; ANTIHYPERTENSIVE AGENT; PRESERVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BURNING SENSATION; CHILD; CONJUNCTIVA DISEASE; CONTROLLED STUDY; CORNEA DISEASE; DRY EYE; EYE IRRITATION; EYELID DISEASE; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR FOREIGN BODY; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PAIN; PRIORITY JOURNAL; PUNCTATE KERATITIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; GLAUCOMA; INCIDENCE; KERATITIS; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CHILD; CONJUNCTIVAL DISEASES; CROSS-SECTIONAL STUDIES; EYELID DISEASES; FEMALE; GLAUCOMA; HUMANS; INCIDENCE; KERATITIS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL;

EID: 34447129594     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210701700311     Document Type: Article

References (30)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2001; 90: 262-67.
2. Wilson LA. To preserve or not to preserve, is that the question? Br J Ophthalmol 1996; 80: 583-4.
3. Dantas PE, Uesugui E, Nishiwaki-Dantas MC, Mimica LJ. Antibacterial activity of anesthetic solutions and preservatives: an in vitro comparative study. Cornea 2000; 19: 353-4.
4. Yalvac IS, Gedikoglu G, Karagoz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand 1995; 73: 246-8.
5. Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol 1975; 59: 667-9.
6. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994; 112: 1437-45.
7. Schwab IR, Linberg JV, Gioia VM, Benson WH, Chao GM. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 1992; 99: 197-202.
8. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994; 112: 1446-54.
9. Ramselaar JA, Boot JP, van Haeringen NJ, van Best JA, Oosterhuis JA. Corneal epithelial permeability after instillation of ophthalmic solutions containing local anaesthetics and preservatives. Curr Eye Res 1988; 7: 947-50.
10. Nguyen TP, Nishimoto JH, Nakamura CY, De Land PN. Comparison of carboxymethylcellulose vs. hydroxypropyl methylcellulose as a gonioscopic fluid. Optom Vis Sci 1996; 73: 466-72.
11. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86: 418-23.
12. van Beek LM, de Keizer RJ, Polak BC, Elzenaar PR, van Haeringen NJ, Kijlstra A. Incidence of ocular side effects of topical beta blockers in the Netherlands. Br J Ophthalmol 2000; 84: 856-9.
13. Bron A, Chiambaretta F, Pouliquen P, Rigal D, Rouland JF. Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of non-preserved beta-blocker in patients with chronic glaucoma or ocular hypertension. J Fr Ophtalmol 2003; 26: 668-74.
14. James EL, Talbot L. Conducting research in general practice: lessons learnt from experience. Health Promot J Austr 2005; 16: 41-6.
15. Lapalus P, Ettaiche M, Fredj-Reygrobellet D, Jambou D, Elena PP. Cytotoxicity studies in ophthalmology. Lens Eye Toxic Res 1990; 7: 231-42.
16. Parnigotto PP, Bassani V, Montesi F, Conconi MT. Bovine corneal stroma and epithelium reconstructed in vitro: characterisation and response to surfactants. Eye 1998; 12: 304-10.
17. Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res 1989; 49: 1-12.
18. Williams DE, Nguyen KD, Shapourifar-Tehrani S, Kitada S, Lee DA. Effects of timolol, betaxolol, and levobunolol on human Tenon's fibroblasts in tissue culture. Invest Ophthalmol Vis Sci 1992; 33: 2233-41.
19. Hamard P, Blondin C, Debbasch C, Warnet JM, Baudouin C, Brignole F. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol 2003; 241: 1037-43.
20. Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol 2003; 121: 835-9.
21. De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40: 619-30.
22. De Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res 2000; 20: 85-94.
23. Takahashi N, Mukai Y. Cytotoxicity of benzalkonium chloride in cell culture. In: Blodi R, Brancato R, Cristini G, et al. Proceedings of the XXVth International Congress of Ophthalmology. Rome. May 4-10, 1986; Acta XXV Conc. Ophtalmol. Amsterdam: Ed. Kugler & Ghedini, 1987; 1: 564-9.
24. Pisella PJ, Lala E, Parier V, Brignole F, Baudouin C. Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eyedrops with and without preservatives in glaucoma patients. J Fr Ophtalmol 2003; 26: 675-9.
25. Manni G, Centofanti M, Oddone F, Parravano M, Bucci M. Interleukin-1 tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol 2005; 139: 72-7.
26. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994; 232: 561-5.
27. Furrer P, Mayer JM, Plazonnet B, Gurny R. Ocular tolerance of preservatives on the murine cornea. Eur J Pharm Biopharm 1999; 47: 105-12.
28. Furrer P, Berger J, Mayer JM, Gurny R. A comparative study of the ocular tolerance of 3 timolol-based preparations: the influence of preservatives on ocular tolerance. J Fr Ophtalmol 2001; 24: 13-9.
29. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23: 490-6.
30. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998; 82: 39-42.